Y-mAbs Therapeutics Datorie 2025

Ce face Y-mAbs Therapeutics?

Y-mAbs Therapeutics, Inc. is a biopharmaceutical company specializing in the development of therapeutics for the treatment of cancer. The company was founded in 2015 and is headquartered in New York City, USA. Y-mAbs was founded by an experienced team of scientists and decision-makers with the goal of creating innovative cancer treatments to improve patients' lives and increase their survival rate. The business model of Y-mAbs is based on the discovery and development of antibodies that target and combat specific cancer cells. Through the use of cutting-edge technologies and advanced research methods, the company has made outstanding progress in cancer therapy. Y-mAbs focuses on precision and personalized medicine to develop innovative therapies tailored to the individual needs of cancer patients. Y-mAbs has several divisions in cancer treatment, including the discovery of novel cancer drugs. The company focuses on the identification of new tumor antigens that could serve as target molecules for the development of immunotherapeutic drugs. Y-mAbs aims to develop personalized and targeted cancer therapies that can identify specific tumor types and genetic mutations. Y-mAbs' portfolio includes a variety of products, including monoclonal antibodies and radioisotope-based drugs for the treatment of metastatic cancer. The company has particularly developed a novel antibody called naxitamab (Danyelza), which is approved for the treatment of neuroblastoma, a rare cancer in children. Naxitamab has been approved by the FDA as a therapeutic option for children with relapsed high-risk neuroblastoma. Y-mAbs has also established a partnership with the University of Texas MD Anderson Cancer Center to advance the development of immunotherapy in cancer treatment. Y-mAbs is also active in the research and development of radioimmunotherapy. The company has developed a radiotherapy platform called omburtamab (Tenodbulin) that specifically targets the glycosylated surface antigen B7-H3. It treats brain cancer and shows promising results. In 2019, the company also completed a groundbreaking Phase 2 study testing a new monoclonal antibody for the treatment of HER2-positive breast cancer. This study demonstrated that the combination of Y-mAbs' monoclonal antibodies with standard drugs showed a higher response in breast cancer patients, leading to potential new treatment options for breast cancer patients. In summary, Y-mAbs Therapeutics, Inc. is an advanced, innovative, and dynamic company focused on the development of personalized cancer therapies. The company strives to improve cancer treatments and extend and enhance the lives of cancer patients through its outstanding research and development. Y-mAbs' products provide a promising option for patients in advanced stages of cancer treatment, hoping for high survival rates. Y-mAbs will continue to invest in the research and development of novel cancer treatments to further improve clinical outcomes. Y-mAbs Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.